

Prostatype Genomics appoints Sedermera Fondkommission as liquidity provider for the company's share

The liquidity providing commences on June 17, 2021

Sedermera Fondkommission will in its assignment as liquidity provider continuously provide trading orders on both bid- and ask side in the orderbook for the Prostatype Genomics share and also ensure that a predetermined spread is kept in the share.

The purpose with liquidity providing is to promote a good liquidity in the share and ensure a low spread between bid and ask prices in the continuous trading.

This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 16-06-2021 17:00 CET.

Fredrik Persson

Media enquiries fredrik.persson@prostatypegenomics.com

Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, ca@skmg.se